MedTrace Logo

Pilot Study on the Pharmacodynamics of Sugammadex in Morbidly Obese Patients: Reversal of Deep Neuromuscular Blockade

NCT01855217 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2013-05-17

No results posted yet for this study

Summary

Should the dose of sugammadex in morbid obese patients be calculated on the real body weight or the ideal body weight?

To study the pharmacodynamics of sugammadex in morbidly obese patients by comparing 1 mg/kg IBW versus 1 mg/kg TBW versus placebo.

Conditions

  • Neuromuscular Blockade

Interventions

DRUG

Sugammadex

1 mg/kg total BW based sugammadex reversal of deep block

DRUG

Sugammadex

1 mg/kg ideal BW based sugammadex reversal of deep block

DRUG

Placebo

0,9% NaCl

Sponsors & Collaborators

  • St. Antonius Hospital

    lead OTHER

Principal Investigators

  • H PA van Dongen · St. Antonius Hospital

Study Design

Allocation
RANDOMIZED
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01855217 on ClinicalTrials.gov